TOKYO, Mar 27 (Pulse News Wire) – TMS Co.,Ltd. (4891.T) announced changes to the allocation timelines for its initial public offering funds and third-party allotment funds.
The adjustments were approved during today's board meeting. Originally, the IPO funds totaling ¥1.320 billion and the third-party allotment funds amounting to ¥500 million were scheduled for allocation until February 2026 and February 2027, respectively, primarily for drug research and pipeline development expenses. Due to optimized external collaborations and cost savings, the company decided to extend the allocation period for the IPO funds to December 2026 and maintain the existing timeline for the third-party allotment funds. As of February 2026, ¥1.113 billion of the IPO funds had been allocated towards direct research and development costs, while the third-party allotment funds remained unallocated.
In detail, the revised allocation plan includes extending the period for direct research and development costs from February 2026 to December 2026, with a planned allocation of up to ¥363 million. Additionally, the human resource and miscellaneous expenses related to research and development for the IPO funds have been fully allocated through fiscal year 2025. For the third-party allotment funds, the operational capital has also been fully allocated according to schedule. Looking ahead, the company expects no impact on its consolidated financial results for the fiscal year ending December 2026 due to these adjustments.
🟡 Confidence: Standard AI-translated content.